ViewMind for pharmaceutical companies

Quantify impact of new drugs on cognitive health

Accurately diagnose neurocognitive disorders. Get access to critical individualized data to complement pathological biomarker results. Achieve better patient outcomes.

Ojaswi Rana

Best Practices Research Analyst

-

Frost& Sullivan

"ViewMind's technology applies to a range of neurocognitive conditions, an exceptional and unique value proposition.
ViewMind has exceptional growth potential, with medical centers, clinics, and elderly care centers rapidly adopting its proprietary technology.
The company’s offering spans the diagnostic continuum, from early stage to disease progression, monitoring, response, and treatment."

Pharmaceutical companies can rely on ViewMind for monitoring of neurocognitive performance and diagnostics

Precise evaluation of neurocognitive performance during clinical trials

Quantify and monitor changes in various neurocognitive resources in response to drug therapies.

Complementary diagnostics and treatment monitoring

Rely on an accurate, non-invasive and standardized evaluation for identifying patients for treatment and measuring treatment progress.

How this works

"Nam ea vivendum explicari comprehensam, eam cibo graeci dissentias in. Ut sententiae elaboraret usu, mei in legendos instructior. Munere aliquid vis ad, id munere legere qui. An sed nulla imperdiet, ex latine splendide mea. Viderer tamquam nominavi id cum, id mei definiebas quaerendum interpretaris, maiorum petentium hendrerit mel cu. Te cum mazim erroribus moderatius, nam ut esse quot. Vis aliquip meliore id. Eam illud ponderum ad, ei atomorum salutandi vis."

Reach out to collaborate on a clinical trial